

Table 1. Baseline characteristics of study participants (n=27)

		Results n = 27
Basic variables	Women (%)	19%
	HD, PD, no-dialysis (%)	67%, 22%, 11%
	Age (years)	60.6 ±14.6
	Height (cm)	176 +9
	Weight (kg)	81.1 +18.5
	Dialysis duration (months)	7.9 (4.5-32.1)
	Aranesp dose (ug/week)	30 (20-50)
	Systolic blood pressure (mmHg)	144±17
	Diastolic blood pressure (mmHg)	81±12
	Cardiovascular disease (%)	15 (n=4)
	Renal transplanted (%)	26% (n =6)
	Diabetes (%)	0
	Number of antihypertensive drugs	2 (1-3)
	ACEi/AT2i (%)	33 (n=9)
	β-blocker (%)	52 (n=14)
	Innohep dosis at HD (IE)	3412 ±1078
Renal diagnosis	Hypertensive nephropathy (%)	15 (n=4)
	Glomerulonephritis (n%)	30 (n=8)
	Interstitiel nephritis (%)	22 (n=6)
	Diabetic nephropathy (%)	0
	Polycystic kidney disease (%)	7 (n=2)
	Unknown (%)	11 (n=3)
	Others (%)	15 (n=4)

Biochemical variables	Hemoglobin (mM)	7.1 ±0.5
	Reticulocyte-hemoglobin (fmol)	2.08 ±0.12
	Reticulocytes (x10 ⁹)	62 ±19
	Folate (nM)	29 (15-45)
	B12 vitamin (pM)	360 (280-540)

DM: Diabetes mellitus; HD: Hemodialysis; PD: Peritoneal dialysis, ACEi: Angiotensin-Converting Enzyme Inhibitors; AT2i: Angiotensin II-receptor blockers.

Table 2. Changes in coagulation parameters with and without ESA and ASA treatment.

Unless otherwise stated, changes in variables are not statistically significant ($p>0.05$)

Parameter	Visit 2 baseline (N=27)	Visit 3 ESA (n=23)	Visit 4 ESA+ASA (n=20)	V5 Wash out (n=15)	Significance
Hematology					
Hb (mM)	6.83 $\pm$ 0.77	6.80 $\pm$ 0.79	7.12 $\pm$ 0.70 ^{bc}	6.93 $\pm$ 0.81	^b 0.018 vs. V2 ^c 0.010 vs. V3
Reticulocyte Hb (fmol)	2.14 $\pm$ 0.11	2.07 $\pm$ 0.09 ^a	2.02 $\pm$ 0.15 ^b	2.13 $\pm$ 0.11 ^f	^a 0.006 vs. V2 ^b 0.006 vs. V2 ^f 0.012 vs. V4
Reticulocytes ($\times 10^9$ /L)	41 $\pm$ 25	72 $\pm$ 25 ^a	69 $\pm$ 24 ^b	36 $\pm$ 18 ^{ef}	^a 0.0000 vs. V2 ^b 0.0000 vs. V2 ^e 0.0000 vs. V3 ^f 0.0000 vs. V4
Leucocytes ($\times 10^9$ /L)	8.1 $\pm$ 3.0	7.4 $\pm$ 2.9	7.5 $\pm$ 3.3	8.3 $\pm$ 3.4	Ns
MCV (fL)	95 $\pm$ 6	97 $\pm$ 5 ^a	98 $\pm$ 6 ^{bc}	94 $\pm$ 6 ^{ef}	^a 0.000 vs. V2 ^b 0.000 vs. V2 ^c 0.018 vs. V3 ^e 0.002 vs. V3 ^f 0.001 vs. V4
Platelet aggregation (Multiplate)					
TRAP (U)	136.5 $\pm$ 34.2	131.1 $\pm$ 26.5	120.0 $\pm$ 28.6	124.1 $\pm$ 31.4	Ns
ADP (U)	80.5 $\pm$ 26.4	73.0 $\pm$ 23.5	62.7 $\pm$ 20.7 ^b	68.6 $\pm$ 20.5	^b 0.032 vs. V2

AA (U)	117 (101-130)	118 (106-139)	29 (21-50) ^{bc}	118 (102-129) ^f	^b 0.000 vs. V2 ^c 0.000 vs. V3 ^f 0.000 vs. V4
ROTEM					
CT EXTEM (s)	61.2 ±9.6	62.6 ±10.2	62.2 7.3	60.9 ±9.6	Ns
CFT (EXTEM) (s)	51.1 ±15.4	48.1 ±11.6	50.3 ±13.0	52.5 ±16.0	Ns
A10 (EXTEM) (mm)	65.3 ±6.3	65.7 ±4.9	65.3 ±5.6	64.7 ±6.1	Ns
MCF (EXTEM) (mm)	70.2 ±5.3	70.4 ±4.2	70.2 ±4.5	69.4 ±5.2	Ns
CT INTEM (s)	159.6 ±25.5	165.0 ±19.5	160.9 ±18.8	166.9 ±28.4	Ns
MCF (FIBTEM) (mm)	28.8 ±10.5	27.3 7±.1	27.3 ±6.0	27.5 ±7.8	Ns
LI30 (EXTEM) (%)	99.2 ±1.6	99.2 ±1.3	98.8 ±2.1	99.3 ±1.3	Ns
Platelet indices					
Plt count (x10 ⁹ /L)	246 ±65	270 ±69 ^a	265 ±62 ^b	245 ±62 ^{ef}	^a 0.006 vs. V2 ^b 0.048 vs. V2 ^e 0.002 vs. V3 ^f 0.010 vs. V4
PDW (fL)	10.5 (9.6-11.6)	10.0 (9.3-11.2) ^a	10.1 (9.4-11.2)	10.1 (9.5-11.2) ^e	^a 0.030 vs. V2 ^e 0.027 vs. V3
MPV (fL)	10.0 ±0.96	9.74 ±0.92 ^a	9.74 ±0.91	9.97 ±0.95 ^{ef}	^a 0.022 vs. V2 ^f 0.024 vs. V4 ^e 0.011 vs. V3
IPC (x10 ⁹ /L)	5.78 (4.25-10.71)	6.02 (3.94-8.32)	4.57 (3.56-8.36)	5.14 (4.25-10.88)	ns
IPF (%)	2.9 (1.7-4.7)	2.1 (1.3-3.6)	2.3 (1.3-3.5) ^b	2.3 (1.8-3.4) ^{ef}	^b 0.034 vs. V2 ^e 0.010 vs. V3 ^f 0.017 vs. V4
H-IPF (%)	0.8 (0.4-1.4)	0.6 (0.4-1.1) ^a	0.6 (0.3-1.2) ^b	0.7 (0.4-1.3) ^{ef}	^a 0.049 vs. V2 ^b 0.018 vs. V2 ^e 0.027 vs. V3

					^f 0.038 vs. V4
Fibrinolysis					
PAI-1 (ng/mL)	10.9 (5.2-32.8)	11.3 (4.3-29.3)	11.3 (7.0-18.4)	6.8 (4.3-12.7) ^{def}	^d 0.010 vs. V2 ^e 0.020 vs. V3 ^f 0.004 vs. V4
tPA (ng/mL)	1.56 (1.06-2.1)	1.61 (1.152.3)	1.67 (1.12-2.5)	1.59 (1.11-2.2)	Ns
Fibrin D-dimer (FEU, mg/L)	0.83 (0.48-1.5)	0.66 (0.52-0.8)	0.68 (0.41-0.9)	0.57 (0.37-0.8)	Ns
<i>Clot formation and lysis assay</i>					
Lag phase (s)	551 (511-637)	542 (518-617) ^a	534 (476-614)	602 (456-705)	^a 0.018 vs. V2
Integral (AU*s)	3025 ±928	3036 ±754	3101 ±847	2743 ±975	Ns
Peak fibrin (AU)	0.895 ±0.194	0.889 ±0.162	0.914 ±0.154	0.847 ±0.182	Ns
Lysis50% (s)	1917 ±266	1953 ±337	2048 ±543	2005 ±531	Ns
Endothelium					
sP-selectin (ng/ml)	43.2 (31.3-53.2)	44.6 (28.5-63.3) ^a	38.1 (28.5-50.9)	36.9 (24.8-53.3) ^e	^a 0.049 vs. V2 ^e 0.004 vs. V3
sThrombomodulin (ng/mL)	50.2 ±17.4	50.4 ±16.5	47.7 ±17.1	48.7 ±18.7	Ns
Procoagulant activity					
F1+F2 (pmol/L)	447 (325-689)	413 (288-513)	361 (309-499)	357 (267-500)	Ns
Inflammation					
CRP (ml/L)	1.71 ±1.18	1.23 ±1.19 ^a	1.53 ±1.27	1.63 ±1.11	0.018 vs. V2

ADP: adenosinediphosphate; Aggr: aggregation; AA: arachidonic acid; BP: blood pressure; CT: clotting time; EXTEM: Extrinsic pathway Thromboelastometry; F1+F2: Prothrombin fragment 1+2; FIBTEM: Fibrinogen thromboelastometry; Hb: hemoglobin; H-IPF: Highly immature platelet fraction; INTEM, intrinsic pathway Thromboelastometry; IPF: immature platelet fraction; MCV: mean corpuscular volume; MPV: mean platelet volume; PAI-1: plasminogen activator inhibitor-1; PDW: platelet distribution width; Plt: platelets; tPA: tissue-type plasminogen activator; TRAP: Trombin Receptor Activating Peptide; ADP: Adenosindiphosphat; V2: visit 2; V3: visit 3; V4: Visit 4; V5: visit 5; CT EXTEM: clotting time EXTEM; CFT EXTEM: Clot formation time (EXTEM); A10 EXTEM: Amplityde 10 min after CT EXTEM; MCF (EXTEM) Maximum clot firmness EXTEM; CT INTEM: clotting time INTEM; MCF (FIBTEM): maximum clot firmness (FIBTEM); LI30 EXTEM = lysis Index 30min after CT (EXTEM)

Normally distributed data are presented as mean $\pm$ SD, and non-normally distributed data as median (IQR).